Insurance does cover Casgevy. Commercial health plans, Medicare, and state Medicaid programs all reimburse the $2.2 million one-time gene therapy for eligible patients 12 and older with sickle cell disease or transfusion-dependent beta thalassemia, and as of early 2026 roughly 90% of U.S. patients have reimbursed access across those payer types.1BioProcess International. Time and Distance: Vertex Tackles Casgevy Access Challenges Coverage is never automatic, though. Every plan requires prior authorization, strict clinical documentation, and treatment at a designated facility, and the criteria are detailed enough that it’s worth knowing them before you start the approval process.
Clinical Criteria Insurers Use to Approve Casgevy
Major insurers including Aetna, Cigna, UnitedHealthcare/Optum, Blue Cross Blue Shield plans, EmblemHealth, Molina, and Blue Shield of California share a common core of eligibility rules drawn from the FDA label and clinical trial data. Specifics vary by plan, but the following requirements come up across the board.
Age and diagnosis. You must be 12 or older with a confirmed diagnosis supported by genetic or molecular testing. For sickle cell, that means genotypes such as βS/βS, βS/β0, or βS/β+. For beta thalassemia, lab documentation of transfusion dependence is required.2Aetna. Exagamglogene Autotemcel (Casgevy)
Disease severity. Sickle cell patients generally need a documented history of severe vaso-occlusive crises over the previous two years. Cigna and several Blue Cross plans require at least four episodes in 24 months,3Cigna. Casgevy Prior Authorization Policy while Aetna and EmblemHealth set the threshold at two per year.4EmblemHealth. Casgevy Coverage Policy For beta thalassemia, transfusion dependence is typically defined as at least 100 mL/kg per year or 10 units of packed red blood cells per year over the preceding two years.5Blue Shield of California. Exagamglogene Autotemcel (Casgevy) Medical Policy
No matched donor available. You cannot have a 10/10 HLA-matched related donor willing to participate in a traditional stem cell transplant.2Aetna. Exagamglogene Autotemcel (Casgevy)
No prior gene therapy or allogeneic transplant. Patients who have already received gene therapy or an allogeneic stem cell transplant are excluded.6Blue Cross Blue Shield of Michigan. Casgevy Medical Policy
Prior hydroxyurea trial for sickle cell. Most plans require that you have tried and failed hydroxyurea or have a documented contraindication.3Cigna. Casgevy Prior Authorization Policy
Medical screening. You must test negative for HIV, hepatitis B, and hepatitis C, with no active infections, advanced liver disease, current malignancy, or certain organ impairments.7Blue Cross NC. Exagamglogene Autotemcel (Casgevy) Notification
One boundary worth knowing: all insurers authorize Casgevy for one dose per lifetime. Retreatment is universally considered experimental and will not be covered.8Excellus BCBS. Casgevy (Exagamglogene Autotemcel) Policy
Plans also control where you get treated. Casgevy must be prescribed by a hematologist or stem cell transplant specialist and administered at a designated facility. Aetna, for example, requires treatment at an “Aetna Institutes GCIT Designated Network” facility unless the plan specifies otherwise.2Aetna. Exagamglogene Autotemcel (Casgevy) Blue Cross NC requires coordination with a specialty pharmacy provider.7Blue Cross NC. Exagamglogene Autotemcel (Casgevy) Notification With roughly 48 authorized treatment centers nationwide, some patients will have to travel out of state.
How Medicare Covers Casgevy
Traditional Medicare fee-for-service covers Casgevy when the treatment is reasonable and medically necessary. Inpatient administration is reimbursed through a Medicare Severity-Diagnosis Related Group payment, and to account for the extraordinary cost, CMS approved a New Technology Add-on Payment for Casgevy’s sickle cell indication with a maximum of $1,650,000 per case. That add-on took effect for discharges on or after October 1, 2024, and runs for a three-year period.9Vertex Pharmaceuticals. Casgevy Coding and Billing Guide
Medicare Advantage plans set their own prior authorization requirements, and reimbursement rates are negotiated between providers and the plan. Clinical criteria usually mirror the commercial side. Aetna’s Medicare Advantage policy, for example, applies the same eligibility rules as its commercial plans.2Aetna. Exagamglogene Autotemcel (Casgevy) If you are enrolled in both Medicare and Medicaid, Medicare pays first.9Vertex Pharmaceuticals. Casgevy Coding and Billing Guide
How Medicaid Covers Casgevy
Medicaid coverage matters more here than for most drugs: an estimated 50% to 60% of Americans living with sickle cell disease are enrolled in Medicaid.10CMS. Biden-Harris Administration Takes Next Steps To Increase Access to Sickle Cell Disease Treatments To help state programs absorb the $2.2 million price tag, CMS launched the Cell and Gene Therapy Access Model in January 2025. CMS negotiates outcomes-based agreements with manufacturers on behalf of participating state Medicaid programs. If the therapy fails to deliver the promised clinical results, the manufacturer provides rebates or price concessions.11CMS. CGT Access Model Frequently Asked Questions
By mid-2026, CMS listed 34 participating Medicaid programs, representing about 84% of Medicaid beneficiaries with sickle cell disease.12CMS. Cell and Gene Therapy Access Model Participating states include California, Texas, New York, Florida, Illinois, Pennsylvania, and Ohio.13HHS. CMS Announces Participation in Cell and Gene Therapy Access Model
The model also addresses some non-drug costs. Participating manufacturers must fund fertility preservation services, including collection, cryopreservation, and storage for five to 15 years, because the chemotherapy conditioning before Casgevy infusion can cause infertility. States without an in-state authorized treatment center must arrange and pay for out-of-state services.11CMS. CGT Access Model Frequently Asked Questions
State implementation timelines vary. New York State Medicaid, for example, began reimbursing Casgevy through its fee-for-service program for managed care members effective January 1, 2026, while maintaining its standard prior authorization process.8Excellus BCBS. Casgevy (Exagamglogene Autotemcel) Policy One access concern worth flagging: advocacy groups have reported that some Medicaid patients have waited more than two years for gene therapy due to state and health plan administrative delays, and Medicaid managed care organizations historically deny about one in eight prior authorization requests across all treatments.14Alliance for Regenerative Medicine. Medicaid Access Barriers for Cell and Gene Therapies
Costs Your Insurance May Not Cover
The $2.2 million list price covers the therapy itself. Even with coverage approved, you may face related expenses that are not fully reimbursed. The preconditioning chemotherapy, extended hospital stays for recovery, and ongoing follow-up monitoring add to the total. Travel to and lodging near one of the roughly 48 authorized treatment centers can be significant if the nearest facility is in another state.15BioPharma Dive. CRISPR Sickle Cell Therapy Price and Cost Issues In Minnesota, for example, there is only one authorized treatment center for Casgevy, so some residents must leave the state for treatment.16Minnesota Department of Commerce. Gene Therapy for Sickle Cell Anemia Evaluation If you are a Medicaid patient in a state that joined the CGT Access Model, out-of-state service costs are supposed to be arranged and paid for by the state.
If You Have Employer-Sponsored Coverage
Most large employers self-insure their health plans, meaning the company pays claims directly rather than buying coverage from a carrier. A single $2.2 million Casgevy claim can exceed a self-insured plan’s budget for the year, and some employers have responded by carving gene therapies out of their standard benefits entirely.17CNBC. Sickle Cell Disease Gene Therapies Insurance and Cost Issues Others buy specialized gene therapy carve-out products from insurers or pharmacy benefit managers, which charge a fixed monthly premium per member and cover approved gene therapy claims. If you have employer coverage, check your Summary Plan Description or ask HR directly whether gene therapies are included, excluded, or routed through a separate carve-out vendor. The answer determines whether your path to approval goes through your regular plan or a different administrator.
Getting Help With Approval
Vertex Pharmaceuticals, Casgevy’s manufacturer, operates a free patient support program called Vertex Connects. Each patient prescribed Casgevy is assigned a dedicated care manager who helps coordinate logistics with authorized treatment centers and provides educational resources on what to expect. Enrollment is not required to receive the therapy, and you can reach the program at 1-833-VERTEX-5.18Vertex Pharmaceuticals. Patient Support On the provider side, Vertex employs access and reimbursement specialists who work with hospitals on payer policies, billing codes, and coverage requirements regardless of insurance type.19Vertex Pharmaceuticals. Cell and Gene Therapy Access and Support Brochure Published Vertex materials do not detail specific copay assistance amounts or programs for uninsured patients, so ask the care manager directly about financial support options for your situation.